(Q44456846)

3 December 2017

Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts (English)

1 reference

3 December 2017

0 references

1 reference

1 reference

L Wang

1

1 reference

3 December 2017

X Huang

2

1 reference

3 December 2017

X Zheng

3

1 reference

3 December 2017

X Wang

4

1 reference

3 December 2017

S Li

5

1 reference

3 December 2017

L Zhang

6

1 reference

3 December 2017

Z Yang

7

1 reference

3 December 2017

9 October 2013

1 reference

Clinical and Translational Oncology

3 December 2017

1 reference

3 December 2017

16

1 reference

3 December 2017

6

1 reference

3 December 2017

567-572

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-013-1120-3

3 December 2017

0 references

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

The role of active surveillance in the management of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

Advances in prostate cancer chemotherapy: a new era begins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

The concurrent chemoradiation paradigm--general principles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

Review of chemoradiotherapy for high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

Practical aspects of weekly docetaxel administration schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

Ionizing radiation decreases capillary-like structure formation by endothelial cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

Microvascular and tumor cell alterations during continuous hyperfractionated irradiation: an electron microscopic investigation on the rat R1H rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-013-1120-3

The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors

21 January 2018

1 reference

12 December 2020

Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

1 reference

12 December 2020

Docetaxel enhances tumor radioresponse in vivo

1 reference

12 December 2020

Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer

1 reference

12 December 2020

Weekly administration of docetaxel (Taxotere): summary of clinical data.

1 reference

12 December 2020

Ionizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis

1 reference

12 December 2020

Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells

1 reference

12 December 2020

Docetaxel/radiation combinations: rationale and preclinical findings

1 reference

12 December 2020

(-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer

1 reference

12 December 2020

10.1007/S12094-013-1120-3

Identifiers

DOI

1 reference

3 December 2017

1 reference